BGI-Shenzhen has acquired Nasdaq-listed Complete Genomics via an all cash tender offer, followed by a short form merger. The deal closed on March 18, 2013. It has been reported as the first time a Chinese company has successfully acquired a US public company. O’Melveny & Myers represented BGI-Shenzhen.
You are browsing the archive for O’Melveny & Myers - peHUB.
Feihe International, a producers and distributors of infant formula, milk powder, and soybean, rice, and walnut products in the People’s Republic of China, is being taken private by Morgan Stanley Private Equity Asia. The deal is valued at US$147 million and expected to close in the second quarter of 2013. O’Melveny & Myers advised the Special Committee of the board of directors of Feihe International.
Dealertrack Technologies is to acquire substantially all of the assets of electronic public license tag agency Casey & Casey NPS. The transaction is valued at approximately US$21.2 million and is expected to close in the second quarter of 2013. O’Melveny & Myers is representing Dealertrack Technologies in the transaction.
Progenics Pharmaceuticals has acquired Molecular Insight Pharmaceuticals, a clinical-stage specialty pharmaceutical company focused on critical unmet diagnostic and therapeutic needs of the prostate cancer patient. O’Melveny & Myers represented Progenics Pharmaceuticals.